29 April 2026
29 April 2026
Ultreon 3.0 uses AI and OCT to provide real-time, high-resolution imaging during minimally invasive heart procedures.
Through working with OpenAI, Massive Bio converts complex clinical trial criteria into machine-readable formats.
A PRV is issued by the FDA to sponsors whose products address certain rare paediatric diseases.
The funds will support further development of Nervonik’s sensing technology and commercialisation of its PNS platform.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
